BioSpace News Archive

Evofem Biosciences, Inc., announced it has reached an agreement with one of the nation’s largest pharmacy benefit managers to ensure most women covered by this plan can fill their Phexxi® prescriptions for pregnancy prevention, without restrictions such as prior authorization or step therapy.

Graybug Vision, Inc. announced that its Board of Directors will conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value.

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the pancreatic cancer cohort of the multi-indication phase 1/2 GOBLET study has met the efficacy expansion criteria for Stage 1 of the trial.

The specialized resource offers patients with rare mutations or fusions in non-small cell lung cancer (NSCLC) and their caregivers access to treatment information, informative webinars, the latest scientific news, and a supportive community.

Elandas, Inc. announced it has merged with long-standing partner AccessSync, LLC, a US-based strategic market access execution services provider.

Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application for its MALT1 inhibitor, SGR-1505.

Soligenix, Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase 2a clinical trial.

Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that biomarker studies that have identified genes that are differentially expressed between healthy individuals and those with Friedreich’s ataxia will be featured in an oral presentation at the upcoming Gordon Research Conference on Mitochondria and Chloroplasts.

JenaValve Technology, Inc. (“JenaValve” or the “Company”), developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, announced positive results from the first Trilogy Heart Valve System commercial implants for high-surgical risk patients with severe, symptomatic aortic stenosis (AS) or aortic regurgitation (AR) in Europe, initially presented at EuroPCR 2022 on May 18.

Sobi® North America announced the launch of the INTO-HLH Registry, a new disease registry for patients with hemophagocytic lymphohistiocytosis.